FDA approves "first ever" device for asthma
This article was originally published in Clinica
Asthmatx's Alair asthma therapy has received premarket approval (PMA) from the US FDA. This makes it the "first ever non-drug treatment for asthma", the Sunnyvale, California company claims. Alair is intended for adults with severe asthma who are already taking the highest doses of conventional asthma drugs (inhaled corticosteroids and long-acting beta-agonists) with little success. The device performs bronchial thermoplasty – using thermal energy to reduce excess airway smooth muscle that is associated with bronchoconstriction. The approval follows a recommendation from an FDA advisory panel in October 2009 (www.clinica.co.uk, 29 October 2009). This was based on results from the AIR2 trial, which found that Alair led to a 32% reduction in severe asthma attacks.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.